Market evolution: Standard dosage medicaments (CN 300490) — 2015–2025

Introduction

This report examines the trade dynamics of CN 300490 — a residual category covering medicaments in measured doses for therapeutic or prophylactic purposes, excluding antibiotics, hormones, alkaloids, vitamins, and antimalarial active principles — traded between the European Union and non-EU countries over the period 2015–2025. The general overview reveals a decade of robust growth: EU export value nearly doubled (+92.5%), reaching €131.2 billion in 2025, while imports grew more moderately (+33.7%) to €43.7 billion. This widening asymmetry has more than doubled the EU's trade surplus, from €35.4 billion in 2015 to €87.4 billion in 2025 (+146.8%). The analysis that follows unpacks the structural, geographic, and price-related drivers of this evolution.

1. A Widening Surplus Driven by Price Appreciation and Expanding Export Volumes

1.1 Export growth outpaced imports across both value and volume

Between 2015 and 2025, the EU's export value surged from €68.1 billion to €131.2 billion, while import value rose from €32.7 billion to €43.7 billion. The trade balance widened accordingly:

1.2 Rising unit values signal a shift toward higher-value medicaments

A striking pattern across the decade is the sharp rise in unit values for both exports and imports. Export prices increased by 54.0% and import prices by 41.2%, reflecting a global shift toward more specialised, higher-priced treatments — a trend consistent with the broader pharmaceutical industry's move toward biologics and specialty drugs. Notably, EU import volumes actually declined by 5.3% over the period, yet import value still rose by 33.7%, underscoring the extent to which price appreciation, rather than volume expansion, has been the dominant driver of import growth.

1.3 The EU's role as a net supplier intensified further

The net import reliance metric stands at −3,556%, indicating that the EU is overwhelmingly a net exporter in this category. In other words, exports exceeded imports by a factor of roughly 36.5 to 1 in 2025. The export propensity remained above 163% throughout the period (meaning exports exceeded domestic production), pointing to the EU's role as a hub for pharmaceutical re-export and contract manufacturing. The trade intensity index hovered between 133% and 144%, confirming that this product category is more trade-oriented than the average EU-manufactured good.

2. Geographic Reorientation: The Rise of Switzerland, the Retreat from the UK, and the US as Primary Growth Engine

2.1 Exports to the United States nearly tripled, making it the largest single destination

The most dramatic shift on the export side has been the surge in trade with the United States. EU exports to the US grew from €15.3 billion to €34.3 billion (+124.0%), making it by far the largest single destination for EU medicaments in 2025. This reflects the strong demand from the US healthcare system for European-manufactured specialty drugs and the competitive positioning of EU pharmaceutical firms in the American market.

2.2 Switzerland became the second-largest export destination, with value multiplying more than sevenfold

Swiss imports from the EU rose from €6.1 billion to €43.1 billion (+611.1%), an extraordinary increase that made Switzerland the second-largest destination by 2025. This likely reflects Switzerland's role as a global pharmaceutical logistics and distribution hub, as well as the integration of Swiss and EU supply chains for companies with cross-border operations. Conversely, EU imports from Switzerland also grew significantly (+140.2%), reaching €16.9 billion, suggesting deep bilateral integration rather than a one-directional flow.

2.3 Brexit contributed to a decline in UK trade flows in both directions

The United Kingdom, which was the largest EU export destination in 2015 (€10.5 billion), saw exports decline by 31.6% to €7.2 billion. Imports from the UK also fell by 35.3%, from €8.3 billion to €5.4 billion. While the UK remains a significant trading partner, its post-Brexit status as a third country appears to have dampened bilateral pharmaceutical trade, potentially due to regulatory divergence and increased friction at borders.

2.4 Emerging markets gained share, while EU exporters diversified

Several smaller partners exhibited rapid growth over the period. India's exports to the EU grew from €0.6 billion to €2.0 billion (+223.5%), and Serbia's from €0.08 billion to €0.28 billion (+261.9%). On the export side, EU shipments to China grew by 82.8% and to South Korea by 93.2%, signalling expanding demand in Asia for EU-origin medicaments.

3. Shifting Production Geography Within the EU and Emerging Price Volatility

3.1 Germany, Ireland, and Slovenia emerged as the leading EU exporters

The distribution of exports by EU Member State shifted notably between 2015 and 2025:

The most remarkable development is Slovenia's rise from a modest €0.8 billion in 2015 to €25.3 billion in 2025, a near-thirtyfold increase. This dramatic growth likely reflects the expansion of contract manufacturing and the positioning of Slovenia as a production base for multinational pharmaceutical firms, perhaps facilitated by Lek (a Sandoz/Novartis subsidiary) and other manufacturers operating in the country. Italy's fourfold increase (+306.1%) similarly points to capacity expansions and Italy's role as a major pharmaceutical manufacturing country.

3.2 Concentration of EU exports increased sharply

The Herfindahl-Hirschman Index (HHI) for export value nearly doubled, from 994 to 1,866 (+87.7%). While still below the 2,500 threshold commonly considered "highly concentrated," this trend reflects the growing dominance of a few Member States — particularly Germany, Slovenia, and Ireland — in EU pharmaceutical exports. Import-side concentration, by contrast, remained relatively stable (HHI around 2,570–2,752), indicating a more persistent and already elevated dependence on a limited number of supplier countries.

3.3 Specialisation patterns reveal a divided pharmaceutical landscape

The revealed comparative advantage analysis for 2025 shows a clear divide. Ireland (RSCA: 0.64) and Slovenia (RSCA: 0.27) are highly specialised in CN 300490, consistent with their role as pharmaceutical manufacturing hubs. By contrast, economies such as Poland (RSCA: −0.63), Czechia (−0.42), and Slovakia (−0.68) display negative specialisation, suggesting that these countries are net importers of medicaments relative to their overall trade profile. This divergence may reflect differing levels of investment in pharmaceutical R&D and manufacturing, as well as the location strategies of multinational firms.

3.4 Price shocks concentrated in 2022 point to pandemic-related supply disruptions

The volatility analysis identifies several significant price shocks, clustered around 2022:

These coincided with the aftermath of the COVID-19 pandemic and the associated supply chain disruptions. The concentration of these shocks in Asian destinations, and specifically in 2022, is consistent with the global scramble for pharmaceutical products during and after the pandemic, as well as with shifts in shipping costs and supply availability that affected pricing.

On the import side, Turkey (coefficient of variation: 0.69) and Mexico (0.60) showed the highest volatility in import flows, suggesting less stable supply relationships compared to traditional partners like Switzerland (0.08) or the United Kingdom (0.19).

Conclusion

Over the 2015–2025 period, the EU's position as a dominant global supplier of standard dosage medicaments (CN 300490) has strengthened considerably. The trade surplus more than doubled to €87.4 billion, driven by a combination of export volume growth (+25%) and significant price appreciation across both export and import flows. Geographically, trade has reoriented markedly: the United States has become the preeminent export destination, Switzerland has emerged as a major hub reflecting deep bilateral integration, while post-Brexit friction contributed to declining trade with the United Kingdom. Within the EU, the export landscape has been reshaped by the extraordinary rise of Slovenia and Italy as production centres, alongside the continued dominance of Germany. The growing concentration of exports (HHI nearly doubling) warrants attention from a supply resilience perspective, even as the EU remains a massive net exporter. Finally, the price shocks observed in 2022 serve as a reminder that this sector — despite the EU's structural strength — remains exposed to global disruptions and geopolitical volatility.